Skip to Main Content

Paper Details

A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Ann Oncol
2
2023
DTC, Lenalidomide, Patients, RAI, VEGFR, cediranib, differentiated thyroid cancer, iodine, iodine 131, lenalidomide, patients, tumor, tyrosine, tyrosine kinase, vascular endothelial growth factor receptor
Author NameAffiliation
David Neil HayesLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill
David Neil HayesLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill
Eric WinquistUniversity of Western Ontario and London Health Sciences Centre
Ezra E W CohenMoores Cancer Center at university of california san diego
  • 1 - 4

Datasets

Release 1.2